43 related articles for article (PubMed ID: 30303146)
1. A Case Study of Gastric Adenocarcinoma and Squamous Cell Carcinoma of the Cervix.
Liu S; Li F; Cao Q; Li N; Gao Q
Onco Targets Ther; 2024; 17():339-344. PubMed ID: 38644954
[TBL] [Abstract][Full Text] [Related]
2. Villoglandular Adenocarcinoma of the Uterine Cervix: A Case Report.
Park S; Pak MG; Park JW
J Menopausal Med; 2023 Dec; 29(3):150-153. PubMed ID: 38230601
[TBL] [Abstract][Full Text] [Related]
3. An Unusual Presentation of Villoglandular Papillary Adenocarcinoma in a Perimenopausal Woman.
Nair PR; Inamdar SA; Kalambe MA; Dewangan A
Cureus; 2024 Feb; 16(2):e54374. PubMed ID: 38505429
[TBL] [Abstract][Full Text] [Related]
4. Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma.
Khoury T; Tan D; Wang J; Intengan M; Yang J; Alrawi S; Yan P; Byrd JC
BMC Clin Pathol; 2006 Jan; 6():1. PubMed ID: 16409624
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in invasive adenocarcinoma of the cervix.
Stolnicu S; Hoang L; Soslow RA
Virchows Arch; 2019 Nov; 475(5):537-549. PubMed ID: 31209635
[TBL] [Abstract][Full Text] [Related]
6. Villoglandular adenocarcinoma of cervix: pathologic features, clinical management, and outcome.
Guo P; Liu P; Yang J; Ren T; Xiang Y
Cancer Manag Res; 2018; 10():3955-3961. PubMed ID: 30310316
[TBL] [Abstract][Full Text] [Related]
7. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification.
Park KJ
Histopathology; 2020 Jan; 76(1):112-127. PubMed ID: 31846527
[TBL] [Abstract][Full Text] [Related]
8. Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.
Nishio S; Mikami Y; Tokunaga H; Yaegashi N; Satoh T; Saito M; Okamoto A; Kasamatsu T; Miyamoto T; Shiozawa T; Yoshioka Y; Mandai M; Kojima A; Takehara K; Kaneki E; Kobayashi H; Kaku T; Ushijima K; Kamura T
Gynecol Oncol; 2019 Apr; 153(1):13-19. PubMed ID: 30709650
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias.
Mandal R; Ghosh I; Banerjee D; Mittal S; Muwonge R; Roy C; Panda C; Vernekar M; Frappart L; Basu P
Int J Gynecol Pathol; 2020 Jul; 39(4):384-390. PubMed ID: 32515923
[TBL] [Abstract][Full Text] [Related]
10. Interlaboratory concordance of p16/Ki-67 dual-staining interpretation in HPV-positive women in a screening population.
Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Carlinfante G; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
Cancer Cytopathol; 2020 May; 128(5):323-332. PubMed ID: 32168431
[TBL] [Abstract][Full Text] [Related]
11. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
12. p16/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology.
Dovnik A; Repše-Fokter A
Diagn Cytopathol; 2020 Jan; 48(1):96-97. PubMed ID: 31714671
[No Abstract] [Full Text] [Related]
13. Evaluation of p16/Ki-67 dual-stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer.
Toliman PJ; Phillips S; de Jong S; O'Neill T; Tan G; Brotherton JML; Saville M; Kaldor JM; Vallely AJ; Tabrizi SN
Clin Microbiol Infect; 2020 Jun; 26(6):748-752. PubMed ID: 31654795
[TBL] [Abstract][Full Text] [Related]
14. p16 Positive Histologically Bland Squamous Metaplasia of the Cervix: What does It Signify?
Goyal A; Ellenson LH; Pirog EC
Am J Surg Pathol; 2020 Jan; 44(1):129-139. PubMed ID: 31498174
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
[TBL] [Abstract][Full Text] [Related]
16. The distribution of novel biomarkers in carcinoma-in-situ, microinvasive, and squamous cell carcinoma of the uterine cervix.
Nicol AF; de Andrade CV; Gomes SC; Brusadelli MG; Lodin HM; Wells SI; Nuovo GJ
Ann Diagn Pathol; 2019 Feb; 38():115-122. PubMed ID: 30579259
[TBL] [Abstract][Full Text] [Related]
17. Villoglandular adenocarcinoma of the uterine cervix: a systematic review and meta-analysis.
Dietl AK; Beckmann MW; Aumann K
Arch Gynecol Obstet; 2021 Aug; 304(2):317-327. PubMed ID: 34036437
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.
Shi L; Lv R; Li C; Han D; Ren Z; Ren G
Transl Androl Urol; 2020 Aug; 9(4):1670-1677. PubMed ID: 32944528
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic and immunohistochemical features of villoglandular adenocarcinoma of uterine cervix.
Huang ZY; Zhang S; Zhang YZ; An JH; Luo J; Liao PJ; Chen Q; Shen H
Indian J Pathol Microbiol; 2018; 61(4):549-552. PubMed ID: 30303146
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
